Mast cells contribute to the resolution of allergic inflammation by releasing resolvin D1.
Allergic inflammation
Allergic peritonitis
Eosinophils
Mast cells
Resolution
Resolvin D1
Journal
Pharmacological research
ISSN: 1096-1186
Titre abrégé: Pharmacol Res
Pays: Netherlands
ID NLM: 8907422
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
received:
13
01
2023
revised:
03
02
2023
accepted:
06
02
2023
pmc-release:
01
03
2024
pubmed:
12
2
2023
medline:
15
3
2023
entrez:
11
2
2023
Statut:
ppublish
Résumé
Mast cells are initiators and main effectors of allergic inflammation, together with eosinophils, with whom they can interact in a physical and soluble cross-talk with marked pro-inflammatory features, the Allergic Effector Unit. The pro-resolution role of mast cells, alone or in co-culture with eosinophils, has not been characterized yet. We aimed to investigate select pro-resolution pathways in mast cells in vitro and in vivo in allergic inflammation. In vitro, we employed human and murine mast cells and analyzed release of resolvin D1 and expression of 15-lipoxygenase after IgE-mediated activation. We performed co-culture of IgE-activated mast cells with peripheral blood eosinophils and investigated 15-lipoxygenase expression and Resolvin D1 release. In vivo, we performed Ovalbumin/Alum and Ovalbumin/S. aureus enterotoxin B allergic peritonitis model in Wild Type mice following a MC "overshoot" protocol. We found that IgE-activated mast cells release significant amounts of resolvin D1 30 min after activation, while 15-lipoxygenase expression remained unchanged. Resolvin D1 release was found to be decreased in IgE-activated mast cells co-cultured with peripheral blood eosinophils for 30 min In vivo, mast cell-overshoot mice exhibited a trend of reduced inflammation, together with increased peritoneal resolvin D1 release. Mast cells can actively contribute to resolution of allergic inflammation by releasing resolvin D1.
Sections du résumé
BACKGROUND
Mast cells are initiators and main effectors of allergic inflammation, together with eosinophils, with whom they can interact in a physical and soluble cross-talk with marked pro-inflammatory features, the Allergic Effector Unit. The pro-resolution role of mast cells, alone or in co-culture with eosinophils, has not been characterized yet.
OBJECTIVES
We aimed to investigate select pro-resolution pathways in mast cells in vitro and in vivo in allergic inflammation.
METHODS
In vitro, we employed human and murine mast cells and analyzed release of resolvin D1 and expression of 15-lipoxygenase after IgE-mediated activation. We performed co-culture of IgE-activated mast cells with peripheral blood eosinophils and investigated 15-lipoxygenase expression and Resolvin D1 release. In vivo, we performed Ovalbumin/Alum and Ovalbumin/S. aureus enterotoxin B allergic peritonitis model in Wild Type mice following a MC "overshoot" protocol.
RESULTS
We found that IgE-activated mast cells release significant amounts of resolvin D1 30 min after activation, while 15-lipoxygenase expression remained unchanged. Resolvin D1 release was found to be decreased in IgE-activated mast cells co-cultured with peripheral blood eosinophils for 30 min In vivo, mast cell-overshoot mice exhibited a trend of reduced inflammation, together with increased peritoneal resolvin D1 release.
CONCLUSIONS
Mast cells can actively contribute to resolution of allergic inflammation by releasing resolvin D1.
Identifiants
pubmed: 36773709
pii: S1043-6618(23)00047-6
doi: 10.1016/j.phrs.2023.106691
pmc: PMC10285510
mid: NIHMS1875331
pii:
doi:
Substances chimiques
Ovalbumin
9006-59-1
resolvin D1
0
Arachidonate 15-Lipoxygenase
EC 1.13.11.33
Immunoglobulin E
37341-29-0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
106691Subventions
Organisme : NIGMS NIH HHS
ID : P01 GM095467
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL122531
Pays : United States
Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interests statement The authors have declared that no conflict of interest exists.
Références
Biochim Biophys Acta. 2007 Sep;1771(9):1156-65
pubmed: 17662651
Sci Immunol. 2017 Mar 10;2(9):
pubmed: 28783702
J Immunol. 2012 Aug 15;189(4):1983-91
pubmed: 22802419
Am J Respir Crit Care Med. 2008 Sep 15;178(6):574-82
pubmed: 18583575
Pharmacol Res. 2022 Apr;178:106172
pubmed: 35278626
Cold Spring Harb Perspect Biol. 2014 Oct 30;7(2):a016311
pubmed: 25359497
J Immunol. 2016 Apr 15;196(8):3429-37
pubmed: 26969756
J Immunol. 2015 Jun 1;194(11):5069-76
pubmed: 25911756
Blood. 2012 Oct 11;120(15):e60-72
pubmed: 22904297
Prostaglandins Other Lipid Mediat. 2020 Oct;150:106477
pubmed: 32711128
JCI Insight. 2017 Jul 20;2(14):
pubmed: 28724795
J Clin Invest. 1991 Apr;87(4):1139-45
pubmed: 2010530
Clin Exp Immunol. 2021 Sep;205(3):306-315
pubmed: 33999404
J Immunol. 1987 Feb 1;138(3):861-7
pubmed: 2433332
Front Immunol. 2012 Aug 28;3:270
pubmed: 22973272
Immunol Rev. 2018 Mar;282(1):151-167
pubmed: 29431215
Infect Immun. 2008 Oct;76(10):4489-97
pubmed: 18644875
Nat Rev Drug Discov. 2016 Aug;15(8):551-67
pubmed: 27020098
J Immunol. 2018 Nov 15;201(10):2998-3005
pubmed: 30315138
J Allergy Clin Immunol. 2022 Jun;149(6):1833-1844
pubmed: 35276243
J Immunol. 2005 Dec 15;175(12):7989-95
pubmed: 16339535
J Leukoc Biol. 2004 Feb;75(2):244-52
pubmed: 14634065
Nature. 2008 Jul 24;454(7203):445-54
pubmed: 18650915
Allergy. 2013 Feb;68(2):171-9
pubmed: 23205534
Methods Mol Biol. 2021;2241:221-242
pubmed: 33486740
J Allergy Clin Immunol. 2013 Feb;131(2):353-60.e1-2
pubmed: 23006546
Allergy. 2011 Mar;66(3):376-85
pubmed: 20977491
Blood. 1998 Jan 1;91(1):64-74
pubmed: 9414270
Immunol Rev. 2018 Mar;282(1):35-46
pubmed: 29431204
J Biol Chem. 2007 Mar 30;282(13):9323-9334
pubmed: 17244615
J Immunol. 2011 Jun 1;186(11):6129-35
pubmed: 21515793
Curr Protoc Immunol. 2010 Aug;Chapter 7:Unit 7.37
pubmed: 20814942
Front Immunol. 2019 May 29;10:1174
pubmed: 31191542
J Exp Med. 2002 Oct 21;196(8):1025-37
pubmed: 12391014
J Clin Invest. 2018 Jul 2;128(7):2657-2669
pubmed: 29757195
Front Immunol. 2016 Apr 26;7:160
pubmed: 27199985
J Allergy Clin Immunol. 2001 Jul;108(1):80-6
pubmed: 11447386
Nat Immunol. 2016 Jul;17(7):878-87
pubmed: 27135604